. L-Arginine increases nitric oxide production in isolated lungs of chronically hypoxic newborn pigs. J Appl Physiol 88: 1797-1803, 2000.-Previously, our laboratory found that pulmonary hypertension developed and lung nitric oxide (NO) production was reduced when piglets were exposed to chronic hypoxia (Fike CD, Kaplowitz MR, Thomas CJ, and Nelin LD. Am J Physiol Lung Cell Mol Physiol 274: L517-L526, 1998). The purposes of this study were to determine whether L-arginine addition augments NO production and to evaluate whether L-arginine uptake is impaired in isolated lungs of chronically hypoxic newborn piglets. Studies were performed by using 1-to 3-day-old piglets raised in room air (control) or 10% O 2 (chronic hypoxia) for 10-12 days. Lung NO production was assessed in isolated lungs from both groups by measuring the perfusate accumulation of nitrites and nitrates (collectively termed NO x Ϫ ) before and after addition of L-arginine (10 Ϫ2 M) to the perfusate. The rate of perfusate NO x Ϫ accumulation increased by 220% (from 0.8 Ϯ 0.4 to 2.5 Ϯ 0.5 nmol/min, P Ͻ 0.05) after L-arginine addition to chronic hypoxic lungs but remained unchanged (3.2 Ϯ 0.8 before vs. 3.3 Ϯ 0.4 nmol/min after L-arginine) in control lungs. In the second series of studies, L-arginine uptake was evaluated by measuring the perfusate concentration of L-[ 3 H]arginine at fixed time intervals. The perfusate concentration of L-[ 3 H]arginine at each time point was less (P Ͻ 0.05) in control than in chronic hypoxic lungs. Thus L-arginine uptake was impaired and may underlie in part the reduction in lung NO production that occurs when piglets are exposed to 10-12 days of chronic hypoxia. Moreover, these findings in isolated lungs lead to the possibility that L-arginine supplementation might increase in vivo lung NO production in piglets with chronic hypoxiainduced pulmonary hypertension.
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neonatal pulmonary hypertension; L-arginine uptake; nitrites; nitrates L-ARGININE IS METABOLIZED by nitric oxide synthase (NOS) into nitric oxide (NO) and L-citrulline. Our laboratory has previously found lower NO production, as measured by the accumulation of the stable metabolic products of NO, nitrites and nitrates (collectively termed NO x Ϫ ), in the perfusate of lungs from piglets with pulmonary hypertension induced by 10-12 days of exposure to chronic hypoxia, compared with comparableage control piglets (11) . This finding leads to the suggestion that decreased lung NO production could contribute to the development of chronic hypoxiainduced pulmonary hypertension in newborn piglets. In turn, it is possible that reduced amounts of the enzyme responsible for basal NO production, endothelial NOS (eNOS), could be a mechanism contributing to the decreased NO production by lungs of the chronically hypoxic piglets. This possibility is supported by our laboratory's previous finding that the amount of eNOS was less in whole lung homogenates from the chronically hypoxic compared with the control piglets (11) . However, another possible mechanism for decreased lung NO production may be that the bioavailability of L-arginine is altered during chronic hypoxia (3, 6, 18, 20) . If this were the case, then additional L-arginine may increase lung NO production by increasing bioavailability of L-arginine to lung eNOS. Evaluation of this possibility is of particular importance because of the implications for therapeutic manipulation of the L-arginine-NO pathway. Therefore, to test the hypothesis that reduced L-arginine bioavailability contributes to reduced NO production in the lungs of chronically hypoxic newborn pigs, we determined whether addition of L-arginine to the perfusate augmented NO production in lungs from chronically hypoxic piglets. Because L-arginine is transported into cells via amino acid transporters (17, 27) , altered uptake is one potential mechanism for reduced L-arginine bioavailability (3). Thus we also evaluated L-arginine uptake in isolated lungs of control and chronically hypoxic newborn piglets.
METHODS

Animals.
A total of 13 chronically hypoxic piglets was studied, and a total of 16 control piglets was studied. Different litters were used for control piglets than for chronically hypoxic piglets. The control piglets were not littermates; therefore, these piglets came from 16 different litters. Some of the chronically hypoxic piglets were littermates, such that these piglets came from nine different litters. For the chronically hypoxic piglets, newborn pigs (1-3 days old) were placed in a hypoxic normobaric environment (chronic hypoxia) for 10-12 days. Normobaric hypoxia was produced by delivering compressed air and nitrogen to an incubator (Thermocare). The O 2 content was regulated at 8-10% O 2 (PO 2 60-72 Torr), and PCO 2 was maintained at 3-6 Torr by absorption with soda lime. The chamber was opened three times a day for cleaning and to weigh the animals. The animals were fed ad libitum with an artificial sow milk replacer from a feeding device attached to the chamber. Some (n ϭ 4) of the control pigs were raised by placing newborn pigs (1-3 days old) in a room-air environment for 10-12 days and maintaining them as described for the hypoxic piglets. Because we previously found no difference in the perfusate accumulation of NO x Ϫ between lungs from control piglets raised on the farm and lungs from control piglets raised in a normoxic chamber (11) , most (n ϭ 12) of the control piglets were studied on the day of arrival from the farm at 11-15 days of age. All piglets were anesthetized for lung isolation and perfusion as described below (see Lung isolation and perfusion). Before lung isolation and perfusion, catheters were placed in some anesthetized control (n ϭ 9) and chronically hypoxic (n ϭ 7) piglets for determination of in vivo pulmonary vascular resistance as follows.
Measurements in anesthetized animals. On the day of study, some control (n ϭ 9) and some chronically hypoxic (n ϭ 7) animals were weighed and anesthetized with ketamine (30 mg/kg im) and pentobarbital (10 mg/kg iv). Additional intravenous pentobarbital sodium was given as needed via an ear vein to maintain anesthesia during placement of the catheters. First, the trachea of the piglet was cannulated so that the animal could be ventilated, if necessary. Then a catheter was placed into the right femoral artery for monitoring systemic blood pressure and arterial blood gases. Another catheter was placed through the right external jugular vein into the pulmonary artery to monitor pulmonary arterial pressure. To obtain the pulmonary wedge pressure, we advanced the pulmonary arterial catheter into a distal pulmonary vessel. The zero reference for the vascular pressures was the midthorax. To measure cardiac output by the thermodilution technique (model 9520, thermodilution cardiac output computer, Edwards Laboratory), we placed a thermistor into the aortic arch via the left femoral artery, and we placed a catheter that served as an injection port into the left ventricle via the left carotid artery. Cardiac output was measured at end expiration as the mean of three injections of 3 ml of 0.9% saline (0°C). After blood gases, pulmonary arterial pressure, pulmonary wedge pressure, and cardiac output were measured, the animals were given additional anesthesia (3-5 mg/kg pentobarbital iv) for lung isolation and perfusion as described below.
Lung isolation and perfusion. All animals were anesthetized as described above, given heparin (1,000 IU/kg iv), and then exsanguinated. For lung isolation and perfusion, the tracheal cannula of each piglet was attached to a large animal piston-type ventilator, and the lungs were ventilated with a normoxic gas mixture (17% O 2 , 6% CO 2 , and balance N 2 ) by using a tidal volume of 15-20 ml/kg and a respiratory rate of 15-20 breaths/min (mean airway pressure of 3-5 mmHg). A midline sternotomy was performed, and a clamp was placed across the ductus arteriosus. Saline-filled cannulas were placed into the pulmonary artery and left atrium through incisions in the right and left ventricles. The diaphragm and all abdominal contents were removed. The lungs were either left in situ (for measurement of perfusate accumulation of NO x Ϫ ) or removed from the thorax (for measurement of L-[ 3 H]arginine uptake). In all lungs, the vascular cannulas were connected to a perfusion circuit that was filled with a Krebs Ringer bicarbonate (KRB) solution containing 5% dextran, mol. wt. 70,000, at 37°C. Briefly, in the perfusion circuit a rotary pump continuously circulated the perfusate from a reservoir through a bubble trap into the pulmonary arterial cannula, through the lungs to the left atrial cannula, and back to the reservoir. Pulmonary arterial, left atrial, and airway pressures were continuously monitored. The most dependent edge of the lung was used as the zero reference for vascular pressures. The height of the reservoir was adjusted to maintain left atrial pressure at 0 mmHg.
Measurement of perfusate accumulation of NO x
Ϫ in isolated lungs. Isolated, perfused lungs from 10 of the control piglets and nine of the chronically hypoxic piglets were used in these studies. Lung perfusion was initially non-recirculating in these studies. When the effluent from the lung was nearly free of blood, recirculating perfusion was initiated such that the perfusate had a Hct Ͻ1%. The volume of recirculating perfusate was adjusted to 130-170 ml, and the flow rate was adjusted to 50 ml · min Ϫ1 ·kg Ϫ1 . The lungs were perfused for 30-60 min until a stable pulmonary arterial pressure was achieved. Perfusate samples (3 ml) were then removed from the left atrial cannula every 10 min for a 60-min baseline period. Next, L-arginine (10 Ϫ2 M) was added to the perfusate, after which perfusate samples were collected every 10 min for an additional 60 min (L-arginine period). The perfusate samples were centrifuged, and the supernatant was stored at Ϫ70°C for future analysis of NO x Ϫ concentrations. At the end of the perfusion, the volume of perfusate remaining in the circuit and reservoir was measured.
A spectrophotometric analysis, which has been described previously (11) , was used for determination of lung perfusate NO x Ϫ concentrations. All reagents were obtained from Sigma Chemical. Fifty microliters of a stock NADPH solution (0.8 µg NADPH/ml phosphate buffer) and 10 µl of a stock nitrate reductase solution (5 units nitrate reductase/ml phosphate buffer) were added to 500 µl of lung perfusate. After incubation for 3 h at room temperature, Greiss reagent [300 µl; 1% sulfanilamide, 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride, and 2.5% phosphoric acid] was added to the lung perfusate and incubated for 10 min at room temperature, and the absorbance was measured at 546 nm. A standard curve was prepared by adding known amounts of NaNO 3 to fresh perfusate. Fresh perfusate with added NADPH, nitrate reductase, and the Greiss reagent as described for the lung perfusate samples was used as a blank. Duplicate assays were carried out for each sample of lung perfusate.
The perfusate NO x Ϫ concentration (nmol/ml) was determined for each collection time as described above. The amount of NO x Ϫ in the perfusate (nmol) at each collection time was calculated by multiplying the perfusate concentration of NO x Ϫ at that sample collection time by the volume of the system (perfusion circuit plus reservoir) at the sample collection time plus the amount of NO x Ϫ removed with all previous samples. The amount of NO x Ϫ accumulated (nmol) was the amount of NO x Ϫ at each collection time minus the amount of NO x Ϫ at time 0. The amount of NO x Ϫ at time 0 was determined from the y-intercept of a linear regression line fit to the amount of NO x Ϫ in the perfusate vs. time for the first 60 min of perfusion.
Measurement of L-[ 3 H]arginine uptake in isolated lungs.
Isolated, perfused lungs from six other control piglets and four other chronically hypoxic piglets were used in these studies. The perfusion circuit for these studies was modified to contain two reservoirs in parallel, both containing KRB, such that the perfusate entering the lungs could be rapidly changed from one reservoir system to the other. The lungs were initially connected to the first reservoir and were perfused for 30-60 min until a stable pulmonary arterial pressure was achieved. During this stabilization period, tritium-labeled L-arginine (L-[2,3,4,5-3 H]arginine monohydrochloride, specific activity 59 Ci/mmol) and enough unlabeled L-arginine to achieve a final perfusate concentration of 10 µM L-arginine were added to the KRB in the second reservoir (25 µCi) . At the end of the stabilization period, a time 0 sample was taken from the second reservoir containing the KRB mixed with L-[ 3 H]arginine. Then the perfusate entering the lung was rapidly switched to this L-[ 3 H]arginine-containing reservoir. The perfusate leaving the lungs was discarded until the volume of perfusate in the lung and the tubing from the lung to the reservoir at the time of the switch were filled with the KRB containing the L-[ 3 H]arginine. At this point, recirculating perfusion from the second reservoir was established, and 200-µl samples of perfusate were collected from the reservoir at 2, 5, 10, 15, 30, and 60 min after switching. To measure the total L-[ 3 H]arginine counts per minute at each sampling time point, we mixed each sample with 5 ml of liquid scintillation counting cocktail and placed them in a liquid scintillation counter. To determine the L-[ 3 H]arginine counts per minute added to the reservoir, two 10-µl aliquots of the L-[ 3 H]arginine that had been added to the perfusate were placed directly into 5 ml of liquid scintillation counting cocktail and were then placed in the liquid scintillation counter.
For each sampling time point, the total L-[ 3 H]arginine counts per minute were corrected for the metabolism of L-arginine to its metabolites, L-ornithine and L-citrulline, by measuring the appearance of 3 H in L-ornithine and L-citrulline using TLC. To do this, at each time point an additional sample of the perfusate (40 µl) was collected and streaked directly on a TLC plate (Silica Gel 60 F254, EM Science), which was run in a mobile phase consisting of chloroformmethanol-ammonium hydroxide-water (9:9:4:1). The retardation factor values are 0.18 for L-arginine, 0.31 for L-ornithine, and 0.66 for L-citrulline. Each TLC plate was scraped in 1-cm bands into a scintillation vial to which 10 ml of scintillation fluid were added. Each vial was placed in a sonicator for 30 s and then into the liquid scintillation counter. The amount of L-[ 3 H]arginine in the perfusate for each time point was determined from the ratio of 3 H in L-arginine to that in its tritiated metabolites and was normalized to the L-[ 3 H]arginine concentration at time 0.
Calculations and statistics. Data are presented as means Ϯ SE. Unpaired t-tests were used to compare the hemodynamic measurements between control and chronically hypoxic animals. The NO x Ϫ accumulation data were analyzed by first determining the rate of NO x Ϫ accumulation (nmol/min) in each lung by linear regression of each individual lung's accumulated NO x Ϫ (nmol) vs. time (min) data for both the baseline and L-arginine time periods. Then the individual rates of NO x Ϫ accumulation (nmol/min) were meaned and compared between control and chronic hypoxic groups for both baseline and L-arginine perfusion periods by using a one-way ANOVA and a post hoc test to determine the significant differences between the two groups and the two perfusion periods. The L-[ 3 H]arginine uptake data were analyzed by using a one-way ANOVA and a Newman-Keuls post hoc test to compare between control and chronically hypoxic animals the amount of L-[ 3 H]arginine in the perfusate at each time point. P Ͻ 0.05 was indicative of statistical significance.
RESULTS
After 10-12 days of hypoxia, the chronically hypoxic piglets weighed less than the corresponding control piglets ( Table 1 ). The measured values of blood pH, PO 2 , and PCO 2 obtained during hemodynamic measurements in anesthetized piglets breathing room air did not differ significantly between control and chronically hypoxic piglets (Table 1) . Similarly, measured values of pH, PO 2 , and PCO 2 in the perfusate of isolated lungs from chronically hypoxic piglets were not significantly different from those of control piglets ( Table 1) .
Measurements of pulmonary arterial pressure, pulmonary wedge pressure, cardiac output, and calculated pulmonary vascular resistance [(pulmonary arterial pressure Ϫ wedge pressure) Ϭ cardiac output] in the anesthetized piglets are shown in Table 2 . Pulmonary arterial pressures and pulmonary vascular resistances were significantly greater in the chronically hypoxic than in the control piglets (Table 2 ).
In the isolated lungs used in the NO x Ϫ accumulation studies, the baseline pulmonary arterial pressures at the end of the stabilization period were higher in lungs from chronically hypoxic than from control piglets ( Table 3 ). With addition of L-arginine to the perfusate, pulmonary arterial pressure decreased by a greater amount in the hypoxic than in the control lungs when expressed as an absolute change in pressure but not when expressed as a percent change in pressure ( Table 3) .
The NO x Ϫ concentration measured in the perfusate at the first collection time and at both the 60-and 120-min collection times was lower in chronically hypoxic lungs than in control lungs at comparable collection times (Table 4 ). In both the chronically hypoxic and control groups, the perfusate NO x Ϫ concentration measured at the 120-min collection time was greater than that measured at the first collection time (Table 4) ; but only in the chronically hypoxic group was the perfusate NO x Ϫ concentration greater at the 120-min collection time Values are means Ϯ SE; n, no. of animals. * Different from control, P Ͻ 0.05, unpaired t-test. Values are means Ϯ SE; n, no. of animals. * Different from control, P Ͻ 0.05, unpaired t-test.
than at the 60-min collection time (Table 4 ). Figure 1 shows the amount of accumulated NO x Ϫ (nmol) in both control and chronically hypoxic animals at each collection time for the 60-min baseline period and the 60-min L-arginine period. At all time points after the first 40 min of the baseline period was the amount of accumulated NO x Ϫ less in the chronically hypoxic than in the control lungs (Fig. 1) . Figure 2 illustrates the perfusate NO x Ϫ accumulation rate (nmol/min) in control and chronically hypoxic animals. During the baseline period, the rate of NO x The data for the measurement of L-[ 3 H]arginine uptake in isolated lungs from control and chronically hypoxic piglets are illustrated in Fig. 3 
DISCUSSION
In agreement with our laboratory's previous study (11) , in this study we show a reduced rate of perfusate NO x Ϫ accumulation in isolated lungs of piglets with chronic hypoxia-induced pulmonary hypertension. An important new finding in this study is that L-arginine addition augmented the rate of perfusate NO x Ϫ accumulation in lungs from chronically hypoxic piglets but did not change the rate in lungs from comparable agecontrol piglets. Another new finding in this study is that L-arginine uptake was impaired in lungs of piglets exposed to chronic hypoxia. Altogether, these findings indicate that the reduction in lung NO production that occurs when newborn piglets are exposed to 10-12 days of chronic hypoxia may be due, at least in part, to impaired bioavailability of L-arginine, the substrate for NO synthesis by the enzyme eNOS.
In addition to reduced substrate availability, a reduction in the enzyme amount could contribute to the decreased NO x Ϫ accumulation rate that we found in lungs of chronically hypoxic piglets. This possibility is supported by our laboratory's previous findings of decreased eNOS amounts in whole lung homogenates of chronically hypoxic piglets (11) . NOS immunoreactivity has been localized in pulmonary vascular endothelium, nerves, and airway epithelium so that the cellular source of the decreased eNOS in the whole lung homogenates could include any or all of these tissues (16) . This issue remains of interest because the lower perfusate NO x Ϫ accumulation rate most likely reflects vascular NO production, not airway NO production. Thus if reduction in enzyme amount contributes to the lower NO perfusate accumulation, then the cellular source of reduced eNOS should include vascular endothelium. However, it is possible that, either in addition to or instead of vascular endothelial cells, airway epithelial cells are the cellular source of reduced eNOS. Support for this latter possibility is provided by our laboratory's previous finding that exhaled NO output is reduced in lungs of chronically hypoxic piglets (11) . To help resolve these issues, the cellular source of the reduced eNOS amounts in whole lung homogenates of chronically hypoxic piglets needs to be determined.
Another issue is that, in our laboratory's previous study, we found that whole lung homogenate eNOS Values are means Ϯ SE; n, no. of animals. * Different from control, P Ͻ 0.05, unpaired t-test. amounts were reduced by 40%, whereas lung perfusate accumulation of NO was reduced by a much larger amount, 62% (11) . This leads to the hypothesis that a mechanism additional to eNOS abundancy might contribute to impaired NO production in lungs of chronically hypoxic newborn piglets.
One possibility is that reduced enzyme activity might also occur during chronic hypoxia. In fact, our measurements of NO production over time reflect enzyme activity, so that our findings support this possibility. As to the cause of altered enzyme activity, oxygen is the electron acceptor in the NOS-mediated synthesis of NO from L-arginine, so that its depletion during chronic hypoxia could impair enzyme activity (21) . This explanation does not seem likely in our studies, as the Michaelis-Menten constant for oxygen for the NOS activity of aortic endothelial cells was recently shown to be ϳ6 mmHg (24) . Furthermore, during the perfusion period, all lungs were ventilated with a gas mixture with a PO 2 of 125 Torr.
Instead of oxygen limitation, impaired L-arginine availability may explain why NO production was low during baseline conditions and then increased with addition of L-arginine to lungs of chronically hypoxic piglets. In other words, our finding that the rate of NO production over time was improved by the addition of L-arginine suggests not only that NOS activity was reduced in the lungs of chronically hypoxic piglets but that the reduction in NOS activity is at least partly due to impaired L-arginine availability. There are only a few other studies in pulmonary hypertensive animals in which NO production in response to exogenous L-arginine has been measured. These studies have been performed in adults, and the results have been inconsis- tent (2, 18) . Although the amount of data for pulmonary hypertension is very limited, quite a few studies have shown that L-arginine increases NO production in animals with other vascular diseases (4, 7, 19, 22) .
The explanation as to why L-arginine supplementation increases NO production remains unclear. Recently it has been found in porcine pulmonary arterial endothelial cells that the cationic amino acid transporter 1 and eNOS form a complex in the caveolae, which suggests that L-arginine transported from the outside of the cell may be directly delivered to eNOS (17) . However, with this as an explanation, one might predict that L-arginine addition would increase NO production in control lungs, which we did not find in this study. Another possibility is that endogenous competitive inhibitors of L-arginine uptake or NOS, such as L-glutamine (1) and/or asymmetric dimethylarginine (4), have accumulated during the disease process. This mechanism is purported to at least partly explain the ability of L-arginine to increase NO production in the atherosclerotic vasculature of cholesterol-fed rabbits (4) .
It is also possible that the chronically hypoxic lungs become L-arginine depleted, which would explain the effect of exogenous L-arginine on NO production. In our study, all lungs were cleared of blood before the onset of perfusion with an L-arginine-free perfusate, after which L-arginine was added to make a concentration of 10 Ϫ2 M. Thus different extracellular L-arginine amounts cannot explain the different perfusate NO x Ϫ accumulation rates in control compared with chronically hypoxic animals in our study. In regard to intracellular amounts, the concentration of L-arginine in normal endothelial cells has been found to be at least 100 µM (1, 15) . Because this amount exceeds the Michaelis-Menten constant of the NOS enzyme, [ϳ5 µM (27) ], excess L-arginine would not be predicted to alter NO production in normal lungs. Indeed, in our study, addition of L-arginine had no effect on the rate of perfusate NO x Ϫ accumulation in the control lungs. However, intracellular depletion of L-arginine may occur during chronic hypoxia and thereby contribute to the reduced lung NO production in these animals.
Impaired uptake is one mechanism that could lead to intracellular depletion of L-arginine. This idea is supported by findings of others showing reduced L-arginine content and impaired L-arginine uptake in endothelial cells from pulmonary arteries of 6-to 7-mo-old pigs cultured under hypoxic conditions for 3-5 wk (3). Our findings in chronically hypoxic newborn piglets are of particular importance because they are the first showing impaired pulmonary vascular arginine uptake resultant from an in vivo model of chronic hypoxia, indicating that the findings are not limited to in vitro experimentation.
Our findings are also important because they provide a mechanistic basis to pursue manipulating the L-arginine-NO pathway in chronic hypoxia-induced pulmonary hypertension. For example, if reduced NO production is involved in the development of chronic hypoxia-induced pulmonary hypertension, correcting NO production by L-arginine addition might ameliorate the development of this disease. This hypothesis is consistent with the finding that treatment with L-arginine during hypoxic exposure restored endotheliumdependent vasodilation in lungs from chronically hypoxic rats (6, 9) . Furthermore, administration of L-arginine to rats during chronic hypoxic exposure ameliorated pulmonary hypertension and vascular remodeling (20) . A limitation of these latter studies is that functional changes were evaluated, but NO production was not assessed. It should also be noted that L-arginine has not always been shown to augment NO function either in pulmonary hypertension (2, 8, 14) or in other vascular diseases (13, 23, 26) .
Along these lines, one might predict that L-arginineinduced vasodilation would correlate with NO production. Our findings are not consistent with this latter prediction, as we found the same vasodilatory response to L-arginine in control and hypoxic lungs even though L-arginine increased NO production in the hypoxic but not in the control lungs. It is possible that either instead of or in addition to an effect from NO production, the decrease in pulmonary artery pressure with L-arginine might have been from a nonendotheliumdependent, nonspecific vasodilatory effect, as has been demonstrated by others (5, 25) . In contrast to our findings in newborn piglets, other investigators have provided evidence for an enhanced vasodilator response to L-arginine in animals with pulmonary hypertension (12, 18) .
The influence of experimental conditions on NO x Ϫ production and L-[ 3 H]arginine uptake should be commented on. Because of the difference in body weights between control and chronically hypoxic animals, differences in lung size might be questioned as a source of both the different baseline NO x Ϫ accumulation rates and the different L-[ 3 H]arginine uptakes measured in perfused lungs of control compared with chronically hypoxic animals. However, even though we previously reported smaller lung dry weights in chronically hypoxic than in control piglets (10), we recently found no difference in vascular volumes in perfused lungs between the two groups (11) . Hence, differences in perfused surface areas are not a likely explanation for the markedly different values for baseline NO x Ϫ accumulation rates and L-[ 3 H]arginine uptake measured in lungs of control compared with chronically hypoxic piglets in this study.
In summary, our findings are consistent with a defect in basal NO production in lungs of chronically hypoxic piglets that can be overcome by the excess substrate L-arginine. This defect appears to be due, at least in part, to impaired transport of L-arginine into pulmonary vascular cells, which in turn could result in a reduction of intracellular L-arginine availability. These findings do not exclude the possibility that another mechanism, such as reduced enzyme abundance, also contributes to impaired NO production. For instance, it is possible that impaired L-arginine uptake by pulmonary vascular endothelial cells is the primary, if not sole, mechanism responsible for decreased lung vascu-lar NO production, whereas reduced eNOS amounts in lung epithelial cells underlie decreased airway NO production. These possibilities require further study. In addition, whether providing excess L-arginine to living piglets would restore functional impairments of the pulmonary vasculature and prevent or inhibit the development of pulmonary hypertension during exposure to chronic hypoxia is an important issue that needs to be investigated.
